Is SVR4 Testing an Acceptable Alternative Measure of HCV Cure in Re-Treated Patients Following DAA Failure? An SVR4/12 Concordance Evaluation From the POLARIS Clinical Trials

Conference Reports for NATAP

The Liver Meeting
AASLD 2025
Washington, D.C.
November 7-11, 2025


Is SVR4 Testing an Acceptable Alternative Measure of HCV Cure in Re-Treated Patients Following DAA Failure? An SVR4/12 Concordance Evaluation From the POLARIS Clinical Trials

	AASLD 2025 Nov 7-11 Wash DC Marc Bourlière1,2, Stephen Shafran3, Meena B Bansal4, Stuart Gordon5, Stefan Zeuzem6, Candido Hernandez7, Renee-Claude Mercier7, Kyle Hammond7, Liyun Ni7, Stacey Scherbakovsky7, Ira M Jacobson8 1Hôpital Saint Joseph, Marseille, France; 2INSERM UMR 1252 IRD SESSTIM Aix Marseille Université, Marseille, France; 3Department of Medicine, University of Alberta, Edmonton, AB, Canada; 4Mount Sinai, New York, NY, USA; 5Henry Ford Health, Detroit, MI, USA; 6Department of Medicine, University Hospital, Goethe University, Frankfurt, Germany; 7Gilead Sciences, Inc., Foster City, CA, USA; 8NYU Langone, New York, NY, USA